Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a developer of advanced vision restoration technologies, announced that debentureholders have converted $1.4 million of their principal into common shares at a price of $0.32 per share, resulting in the issuance of 4,375,000 common shares. The conversion represents 35% of the Company's previously outstanding debenture principal of $4 million.
This debt conversion significantly strengthens Ocumetics' balance sheet as the company advances toward key milestones in its ongoing patient study program. The conversion of debt into equity is expected to improve the Company's financial flexibility and reduce ongoing interest costs while aligning investor interests with the continued advancement of Ocumetics' technology platform and clinical development objectives.
“These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision,” said Dean Burns, President and CEO of Ocumetics. “We are actively managing our investments and stakeholder relationships as we continue to advance our patient study and focus on achieving the next major milestones for the Company.”
The Company continues to advance toward key regulatory milestones, including preparation for its planned Investigational Device Exemption (“IDE”) submission to the U.S. Food and Drug Administration. Ocumetics is in the first-in-human early feasibility study phase of a dynamic intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens is intended to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses, and without perceptible time lag.
This debt conversion reduces ongoing interest obligations, which could free up capital for research and development. For industry observers, the move signals that investors maintain confidence in Ocumetics' technology as it approaches critical regulatory submissions. A successful IDE submission would be a significant step toward commercialization, potentially disrupting the ophthalmology market with a solution that could reduce dependence on glasses and contact lenses.
Ocumetics is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company's technology has the potential to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.
